

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>MERIDIAN VENTURE PARTNERS II LP</u>  (Last) (First) (Middle) 259 N. RADNOR-CHESTER ROAD SUITE 130  (Street) RADNOR PA 19087  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ANI PHARMACEUTICALS INC [ ANIP ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/12/2014	
	4. If Amendment, Date of Original Filed (Month/Day/Year) 03/14/2014	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/12/2014		S		32,802 <sup>(1)</sup>	D	\$33.61 <sup>(1)(2)</sup>	2,786,942 <sup>(1)</sup>	D <sup>(3)</sup>	
Common Stock	03/12/2014		S		2,517 <sup>(1)</sup>	D	\$34.33 <sup>(1)(4)</sup>	2,784,425 <sup>(1)</sup>	D <sup>(3)</sup>	
Common Stock	03/13/2014		S		33,514 <sup>(1)</sup>	D	\$31.05 <sup>(1)(5)</sup>	2,750,911 <sup>(1)</sup>	D <sup>(3)</sup>	
Common Stock	03/13/2014		S		12,138 <sup>(1)</sup>	D	\$32.53 <sup>(1)(6)</sup>	2,738,773 <sup>(1)</sup>	D <sup>(3)</sup>	
Common Stock	03/13/2014		S		6,752 <sup>(1)</sup>	D	\$33.31 <sup>(1)(7)</sup>	2,732,021 <sup>(1)</sup>	D <sup>(3)</sup>	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)					

1. Name and Address of Reporting Person\*  
MERIDIAN VENTURE PARTNERS II LP  
 (Last) (First) (Middle)  
 259 N. RADNOR-CHESTER ROAD  
 SUITE 130  
 (Street)  
 RADNOR PA 19087  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Meridian Venture Partners II GP, L.P.  
 (Last) (First) (Middle)  
 259 N. RADNOR-CHESTER ROAD  
 SUITE 130  
 (Street)  
 RADNOR PA 19087  
 (City) (State) (Zip)

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Meridian Venture Partners II, Co.

(Last) (First) (Middle)

259 N. RADNOR-CHESTER ROAD  
SUITE 130

(Street)

RADNOR PA 19087

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Brown Robert E. JR

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.  
210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

**Explanation of Responses:**

1. On March 14, 2014, the reporting person filed a Form 4 that reported sales of the Issuer's securities, which Form 4 contained an inadvertent error in the amount of securities beneficially owned following the reported sales transaction. This Form 4 also corrects the method of reporting the prices of the securities sold.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.20 to \$34.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
3. Meridian Venture Partners II, Co. (MVP Corp.) is the general partner of Meridian Venture Partners II GP, L.P. (GP), the general partner of Meridian Venture Partners II, L.P. (MVP II). Robert E. Brown, Jr., a director of the issuer, is the President, sole stockholder and sole director of MVP Corp., as well as a limited partner of GP and one of two principals of MVP II.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.20 to \$34.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.00 to \$31.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$32.05 to \$32.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.20 to \$33.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.

/s/ Robert E. Brown, Jr.

03/18/2014

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**